Korea Arlico Pharm Co.,Ltd. Stock: price and insider trades · South Korea

This page follows insider dealings at Korea Arlico Pharm Co.,Ltd. as filed with DART (FSS), a company from the Health Care sector. From 10 November 2025 to 10 November 2026, the disclosure feed for Korea Arlico Pharm Co.,Ltd. logged 9 filings by 5 insiders.

On the market, 2 insiders bought (2 purchases) while 2 insiders sold (4 sales). The amount is not disclosed for 6 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 board member and 1 chief executive among the declarants.

Across the 2,630 companies tracked on its exchange, the median is 7 filings; at 9 filings, this issuer sits above that mark. Our records for Korea Arlico Pharm Co.,Ltd. go back to 2021, with 2 purchases and 13 sales on the open market in total.

The last purchase on record was published on 15 October 2026, which is 26 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 4 days. That lag is the time during which only the insider knows about the trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

For comparison within the same sector, see the insider buying recorded at MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.